StockpollyBeta
Get App
NUVL · NASDAQ · Biotechnology

Nuvalent (NUVL)

Developer of selective kinase inhibitors targeting ROS1 and ALK resistance in lung cancer.

$123.96
0.00 (0.00%)
Delisted · Jul 16, 2026

Something off on this page? Send us feedback.

13F · 13D/G · Form 4

Insiders28.51%22.52M shares
5 holders · as of Jul 17, 2026
Strategic holders15.94%12.59M shares
2 holders · as of May 6, 2026
Other55.55%43.89M shares
remainder

79.00M company shares as of Sep 23, 2026 · holders as of their latest filing

This company has 2 share classes; every stake here is a share of the whole company.

13F · 13D/G · Form 4

HolderStakeSharesDate
James E. Flynn1Insiderdirector, 10 percent owner, other: Director by Deputization
24.66%22.85M COMPANYfiled Jul 17, 2026
FMR LLCStrategic
11.71%9.25Mfiled May 6, 2026
BlackRock, Inc.Strategic
4.23%3.34Mfiled Jul 17, 2025
Matthew ShairInsiderdirector
2.00%1.58M Afiled Nov 26, 2025
Andrew A. F. HackInsiderdirector
1.83%1.45M Afiled Dec 13, 2024
Ron SquarerInsiderdirector
0.01%6,281 Afiled Jun 18, 2026
Joseph PearlbergInsiderdirector
0.01%5,146 Afiled Jun 20, 2025
Bain Capital Life Sciences Fund II, L.P.Institution
—5.60% of class, as filed—filed Aug 4, 2021
Alexandra BalcomInsiderofficer: Chief Financial Officer
0.00%0filed Jul 15, 2026
Grant C. BogleInsiderdirector
0.00%0filed Jul 15, 2026
Benjamin LaneInsiderofficer: See Remarks
0.00%0filed Jul 15, 2026
Michael L. MeyersInsiderdirector
0.00%0filed Jul 15, 2026
Deborah Ann MillerInsiderofficer: Chief Legal Officer
0.00%0filed Jul 15, 2026
Darlene Noci2Insiderofficer: Chief Development Officer
——filed Jul 15, 2026
Christy J. OligerInsiderdirector
0.00%0filed Jul 15, 2026
Henry E. PelishInsiderofficer: Chief Scientific Officer
0.00%0filed Jul 15, 2026
Perceptive Advisors LLCInstitution
—5.10% of class, as filed—filed Jan 2, 2024
James Richard PorterInsiderdirector, officer: President and CEO
0.00%0filed Jul 15, 2026
Anna ProtopapasInsiderdirector
0.00%0filed Jul 15, 2026
Sapna SrivastavaInsiderdirector
0.00%0filed Jul 15, 2026
Tomas KiselakInsider
—5.13% of class, as filed—filed Nov 9, 2022
Christopher Durant TurnerInsiderofficer: Chief Medical Officer
0.00%0filed Jul 15, 2026
Cameron WheelerInsiderdirector
0.00%0filed Jul 15, 2026
Emily Conley3,2Insiderdirector
——filed Aug 27, 2024
Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington4Insider10 percent owner
1.14%897,671 Afiled Aug 3, 2021
  1. James E. Flynn's transaction reports restate only vehicles that traded; the 2026 ownership statement (22.85M) less the 3.37M net shares sold since is used instead.
  2. The filed share classes (A, COMMON) could not be matched to the company's, so no percentage.
  3. Last filed Aug 27, 2024; leaving the company requires no filing. Not in the bar.
  4. Last filed Aug 3, 2021; leaving the company requires no filing. Not in the bar.

13F

No 13F holders on record.

13D/G · 5% or more, as filed

Holder% of classSharesFormFiled
Deerfield Management Company, L.P.24.21%22.85M13GFeb 12, 2026
FMR LLC12.60%9.25M13GMay 6, 2026
BlackRock, Inc.5.00%3.34M13GJul 17, 2025

Form 4

Latest trades

DateInsiderTypeSharesAvg priceOwned after
Jul 9, 2026
Henry E. Pelishofficer: Chief Scientific Officer
Sale2,111$123.8163,493
Jul 6, 2026
James Richard Porterdirector, officer: President and CEO
Sale30,000$123.72324,879
Jul 1, 2026
Alexandra Balcomofficer: Chief Financial Officer
Sale11,430$123.5885,533
Jul 1, 2026
Darlene Nociofficer: Chief Development Officer
Sale23,000$123.5958,117
Jun 29, 2026
Darlene Nociofficer: Chief Development Officer
Sale5,500$123.5158,117
Jun 9, 2026
Darlene Nociofficer: Chief Development Officer
Sale20,000$122.8158,117
Jun 8, 2026
James Richard Porterdirector, officer: President and CEO
Sale · 3 lots30,000$88.53324,879
May 28, 2026
Deborah Ann Millerofficer: Chief Legal Officer
Sale · 4 lots5,500$107.8459,634
May 28, 2026
Darlene Nociofficer: Chief Development Officer
Sale · 5 lots5,500$107.8058,117
May 4, 2026
James Richard Porterdirector, officer: President and CEO
Sale · 5 lots30,000$101.69324,879

House and Senate disclosures

Not reported.